Individualization of theophylline dosage using a single serum sample following a test dose. 1982

G G Shapiro, and J R Koup, and C T Furukawa, and W E Pierson, and M Gibaldi, and D Fuquay, and C W Bierman

Because formulas for theophylline requirement based on weight alone carry the risk of overdosing and toxicity, this study was designed to test a clearance nomogram for determining daily theophylline requirement after a known initial dose of theophylline. Twenty asthmatic children who had not taken theophylline for at least 36 hours fasted and were given one dose of anhydrous theophylline (5 mg/kg). Six hours later the serum level was measured and the appropriate dosage of sustained-release theophylline to achieve a serum level of 10 micrograms/ml was selected from the clearance nomogram. Three to seven days later a six-hour theophylline level was obtained. Of 20 patients, therapeutic levels of 10 to 30 micrograms/ml were achieved in 15, and the remaining five patients had levels close to this (range 6.2 to 16.0 micrograms/ml). The dosage requirement per 24 hours ranged from 10 to 32 mg/kg/24 hr. This method of determining theophylline requirements for children required measurement of the serum theophylline level only once for the determination of a safe and effective daily dose. It is especially valuable when follow-up is difficult and is a safe way to avoid serious overdosing while being certain of effective dosing.

UI MeSH Term Description Entries
D007206 Individuality Those psychological characteristics which differentiate individuals from one another. Individual Differences,Difference, Individual,Differences, Individual,Individual Difference
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001249 Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). Asthma, Bronchial,Bronchial Asthma,Asthmas
D013806 Theophylline A methyl xanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Theophylline inhibits the 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE that degrades CYCLIC AMP thus potentiates the actions of agents that act through ADENYLYL CYCLASES and cyclic AMP. 1,3-Dimethylxanthine,3,7-Dihydro-1,3-dimethyl-1H-purine-2,6-dione,Accurbron,Aerobin,Aerolate,Afonilum Retard,Aquaphyllin,Armophylline,Bronchoparat,Bronkodyl,Constant-T,Elixophyllin,Euphylong,Glycine Theophyllinate,Lodrane,Monospan,Nuelin,Nuelin S.A.,Quibron T-SR,Slo-Phyllin,Somophyllin-T,Sustaire,Synophylate,Theo Von Ct,Theo-24,Theo-Dur,Theobid,Theocin,Theoconfin Continuous,Theodur,Theolair,Theolix,Theon,Theonite,Theopek,Theophylline Anhydrous,Theophylline Sodium Glycinate,Theospan,Theostat,Theovent,Uniphyl,Uniphyllin,Uniphylline,1,3 Dimethylxanthine,Anhydrous, Theophylline,Constant T,ConstantT,Ct, Theo Von,Glycinate, Theophylline Sodium,Quibron T SR,Quibron TSR,Slo Phyllin,SloPhyllin,Sodium Glycinate, Theophylline,Somophyllin T,SomophyllinT,Theo 24,Theo Dur,Theo24,Theophyllinate, Glycine,Von Ct, Theo
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

G G Shapiro, and J R Koup, and C T Furukawa, and W E Pierson, and M Gibaldi, and D Fuquay, and C W Bierman
January 1982, The Journal of pediatrics,
G G Shapiro, and J R Koup, and C T Furukawa, and W E Pierson, and M Gibaldi, and D Fuquay, and C W Bierman
January 1981, Acta medica Scandinavica,
G G Shapiro, and J R Koup, and C T Furukawa, and W E Pierson, and M Gibaldi, and D Fuquay, and C W Bierman
September 1986, Drug intelligence & clinical pharmacy,
G G Shapiro, and J R Koup, and C T Furukawa, and W E Pierson, and M Gibaldi, and D Fuquay, and C W Bierman
January 1984, European journal of clinical pharmacology,
G G Shapiro, and J R Koup, and C T Furukawa, and W E Pierson, and M Gibaldi, and D Fuquay, and C W Bierman
October 2001, Bone marrow transplantation,
G G Shapiro, and J R Koup, and C T Furukawa, and W E Pierson, and M Gibaldi, and D Fuquay, and C W Bierman
January 1986, Chest,
G G Shapiro, and J R Koup, and C T Furukawa, and W E Pierson, and M Gibaldi, and D Fuquay, and C W Bierman
January 1985, Pharmacology,
G G Shapiro, and J R Koup, and C T Furukawa, and W E Pierson, and M Gibaldi, and D Fuquay, and C W Bierman
April 1986, Chest,
G G Shapiro, and J R Koup, and C T Furukawa, and W E Pierson, and M Gibaldi, and D Fuquay, and C W Bierman
September 1991, Therapeutic drug monitoring,
G G Shapiro, and J R Koup, and C T Furukawa, and W E Pierson, and M Gibaldi, and D Fuquay, and C W Bierman
January 2006, Pharmazie in unserer Zeit,
Copied contents to your clipboard!